Revolution Medicines $264.5 million follow-on offering
The shares are listed on Nasdaq
Davis Polk advised the underwriters in connection with a public offering at $20.00 per share of 13,225,000 shares of common stock of Revolution Medicines, Inc. (which includes the exercise in full by the underwriters of their option to purchase up to 1,725,000 additional shares), for total gross proceeds of $264.5 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “RVMD.”
Based in Redwood City, California, Revolution Medicines is a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.
The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jason Bassetti and associate Jiachen (Lucy) Wang. The intellectual property and technology transactions team included partner David R. Bauer and associate Alison T. Chin. The tax team included partner Michael Farber and associates Tyler Scheiner and Betsy Johnson. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.